GlassScriptPhysician profile
Jeffrey R Boyd
NPI 1255498366
$1,999.43
in general payments reported to CMS, 2019-2025
22 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $68.80 · 2021: $253 · 2022: $402 · 2023: $279 · 2024: $397 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897 · Honoraria: $53.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.18 |
| Honoraria | $53.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $420.20 | 2019-2024 | Tecnis Iol, Catalys System |
| Alcon Vision LLC | $344.23 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $244.86 | 2022-2025 | Vyzulta, Envista Envy Iol, Ic-8 Apthera Iol |
| Abbvie INC. | $167.21 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan |
| Rxsight INC | $103.00 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Allergan, INC. | $99.36 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $86.25 | 2019-2022 | |
| Dompe US, INC. | $77.40 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $69.32 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Aerie Pharmaceuticals, INC. | $54.67 | 2019-2021 | |
| Harrow Eye, LLC | $40.23 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $35.61 | 2019-2021 | |
| Sight Sciences, INC. | $31.22 | 2021-2022 | |
| New World Medical,INC. | $28.04 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $26.86 | 2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $25.17 | 2024 | Xdemvy |
| Rayner Intraocular Lenses Limited | $24.40 | 2025 | Omidria |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $12.83 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.67 | 2022 | |
| Horizon Therapeutics Plc | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.